Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
暂无分享,去创建一个
D. Hipfner | M. Kuwano | T. Abe | S. Naito | S. Cole | R. Deeley | J. Kumazawa | R. Deeley | S. Hasegawa | S. Kotoh
[1] K. Kohno,et al. Possible involvement of multidrug‐resistance‐associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells , 1994, International journal of cancer.
[2] A. Fojo,et al. Cellular control of human multidrug resistance 1 (mdr-1) gene expression in absence and presence of gene amplification in human cancer cells. , 1994, The Journal of biological chemistry.
[3] S. Aaronson,et al. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. , 1994, Cancer research.
[4] M. Barrand,et al. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. , 1994, Journal of the National Cancer Institute.
[5] D. Hipfner,et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.
[6] M. Center,et al. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. , 1993, Cancer research.
[7] M. Slovak,et al. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. , 1993, Cancer research.
[8] F. Baas,et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. , 1993, Cancer research.
[9] M. Slovak,et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.
[10] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[11] M. Kuwano,et al. Polyoma middle T antigen or v-src desensitizes human epidermal growth factor receptor function and interference by a monensin-resistant mutation in mouse Balb/3T3 cells. , 1992, Experimental cell research.
[12] H. Takano,et al. DNA topoisomerase-targeting antitumor agents and drug resistance. , 1992, Anti-cancer drugs.
[13] T. Tsuruo,et al. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. , 1992, The Journal of urology.
[14] D. Marquardt,et al. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. , 1992, Cancer research.
[15] H. Takano,et al. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. , 1991, Cancer research.
[16] H. Takano,et al. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. , 1990, Cancer research.
[17] Michael J. Hartshorn,et al. Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport , 1990, Nature.
[18] K. Kohno,et al. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. , 1990, Cancer research.
[19] H. Takano,et al. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. , 1989, Biochemical and biophysical research communications.
[20] I. Pastan,et al. Expression of Multidrug Resistance Gene in Human Cancers , 1989 .
[21] H. Takano,et al. Vincristine‐resistant Human Cancer KB Cell Line and Increased Expression of Multidrug‐resistance Gene , 1988, Japanese journal of cancer research : Gann.
[22] I. Pastan,et al. The multidrug transporter, a double-edged sword. , 1988, The Journal of biological chemistry.
[23] V. Ling,et al. Mechanism of multidrug resistance. , 1988, Biochimica et biophysica acta.
[24] N. Geller,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.
[25] V. Laudone,et al. An overview of intravesical therapy for superficial bladder tumors. , 1987, The Journal of urology.
[26] J. Trent,et al. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. , 1987, Cancer research.
[27] M. Center,et al. Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. , 1987, Cancer research.
[28] M. Kuwano,et al. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. , 1986, Cancer research.
[29] J. Bubeník,et al. Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen , 1973, International journal of cancer.
[30] K. Cowan,et al. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. , 1994, Cancer research.
[31] J. Kumazawa,et al. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. , 1992, European urology.
[32] S. Mirski,et al. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.